<h4>Background</h4>Sodium-glucose cotransporter-2 (SGLT2) inhibitors are increasingly prescribed for heart failure and chronic kidney disease, irrespective of diabetic status. The gene discussed is SLC5A2; the disease is chronic kidney disease.